Preos “Approvable” Pending Additional Clinical Data, NPS Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA concerns regarding hypercalcemia and Preos’ injection device call for additional safety information for the osteoporosis therapy.
You may also be interested in...
AstraZeneca Will Take Over mGluR Program From NPS Pharmaceuticals For $30 Million
NPS says it will use the money to fund further development of late-stage candidates Preos and Gattex.
AstraZeneca Will Take Over mGluR Program From NPS Pharmaceuticals For $30 Million
NPS says it will use the money to fund further development of late-stage candidates Preos and Gattex.
NPS Downsizes, Seeks Partners To Develop Preos And Teduglutide
Firm will reduce its workforce to 35 and focus on outsourcing and partnering to bring the two Phase III compounds to market.